NRT competition
This article was originally published in The Tan Sheet
Executive Summary
Pfizer's NDA for its smoking cessation drug varenicline tartrate has been granted a six-month priority review by FDA, the firm announces Dec. 21. The product would be marketed as an Rx drug under the brand name Champix if approved. According to Pfizer, the brain's nicontinic receptor triggers a sense of satisfaction when nicotine is inhaled, but the effects recede quickly, creating a cycle of craving and withdrawal. Varenicline is designed to activate the nicotinic receptor to "reduce both the severity of the smoker's craving and the withdrawal symptoms," the firm maintains. Pfizer notes that priority reviews are assigned to drugs "that may provide a significant therapeutic advance over existing therapies." The drug's NDA was submitted in November...
You may also be interested in...
Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says
The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.
The Aspirin Test For AI?
US FDA Commissioner Robert Califf tells Congress that regulators don’t have to know how artificial intelligence works in medicine, but must make very sure it actually does work.
Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire
Clarke helped launch GDUFA I and negotiate GDUFA II, chaired the CDER Executive Committee and oversaw many other programs in the US FDA’s drugs center.